Novonesis (Novozymes) B Class B

NSIS B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
sJGLOCK|TpQLOCK|CJkbJbR

Novonesis Earnings: Innovation and Emerging Markets Drive Another Solid Quarter

Novonesis reported third-quarter organic sales growth of 6%, with continued robust volume growth across divisions. Results came in ahead of the company-compiled consensus, and the full-year organic growth guidance was tightened to the upper end of the range, sending shares up 7% on Nov. 6.

Sponsor Center